In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Na Zhao *Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education; School of Basic Medical Sciences, Gannan Medical University, Ganzhou, China. na.zhao@gmu.edu.cn.ORCID 0009-0005-4852-7439 Joshua Seun Olajide *Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.ORCID 0000-0003-3109-5914 Zhihong Guan *Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.ORCID 0009-0006-2925-396X Junyun HuangGanzhou Key Laboratory of Microbiology and Precision Diagnosis and Treatment; Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.ORCID 0009-0009-7682-494X Xiubin ZouKey Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education; School of Basic Medical Sciences, Gannan Medical University, Ganzhou, China.
Feilong OuPrecise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.ORCID 0009-0006-4862-9969 Jiejing LinPrecise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.ORCID 0009-0004-3821-6111 Tianfu TaoPrecise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.
Tinghai ZhouPrecise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China.
Zongliang GaoGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-8257-8986 Zemin RenDepartment of Basic Medical Sciences, Wuxi School of Medicine; Jiangnan University, Wuxi, China.ORCID 0009-0006-0691-8789 Xiaoxia ShiSchool of Life Sciences, Liaoning Provincial Key Laboratory of Biotechnology and Drug Discovery, Liaoning Normal University, Dalian, China.ORCID 0000-0003-1753-241X Xiaotian HuangKey Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education; School of Basic Medical Sciences, Gannan Medical University, Ganzhou, China. 554131725@qq.com.
Gang WangPrecise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, China. wanggang.v@gzhu.edu.cn.ORCID 0000-0002-2425-4385 Funding
National Natural Science Foundation of China (National Science Foundation of China) 32060040National Natural Science Foundation of China (National Science Foundation of China) 82271909National Natural Science Foundation of China (National Science Foundation of China) 82300674
6 · The paper itselfAbstract
Current dual base editors and hypermutators exhibit limited types of base conversion and constrained mutational diversity. To address this challenge, we engineer a compact dual base editor "A&GBE" by fusing a deaminase and glycosylase with nickase Cas9 (nCas9) to enable concurrent adenine and cytosine editing. Furthermore, we develop quadruple base mutating modules (QBMM) by fusing nickase or dead Cas9 with engineered thymine-DNA glycosylase (TDG), N-methylpurine DNA glycosylase (MPG) and TadA8e, together with MS2-MCP system recruited activation-induced cytidine deaminase (AID). This QBMM enables simultaneous mutation of all four types of nucleotide bases (A, T, G, C) within an approximately 100 base pair (bp) sequence surrounding the gRNA target site. This platform generates hyper diverse multi-nucleotide variants, establishing a powerful tool for accelerated protein evolution, functional genomics, and disease modeling.
Indexed as
MutationAdenineAICDA (Activation-Induced Cytidine Deaminase)AnimalsBase SequenceCRISPR-Cas SystemsCytidine DeaminaseCytosineDeoxyribonuclease IDNA GlycosylasesHEK293 CellsHumansMutagenesisAdenineAICDA (Activation-Induced Cytidine Deaminase)Cytidine DeaminaseCytosineDeoxyribonuclease IDNA Glycosylases
Identifiers
PMID42806035
PMCPMC13619609
What OpenQuestion holds
Textmetadata
Read underepoch 390